Halozyme (HALO) AI Stock Analysis

• Market Cap: $8.01B
• Dividend Yield: N/A
• Average Volume (3M): 2.17M
• Price to Earnings (P/E): 14.3
• Beta (1Y): 0.39
• Revenue Growth: 31.19%
• EPS Growth: 59.01%
• Country: US
• Employees: 350
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.72
• Shares Outstanding: 117,597,000
• 10 Day Avg. Volume: 1,887,777
• 30 Day Avg. Volume: 2,165,663
• PEG Ratio: 0.21
• Price to Book (P/B): 16.67
• Price to Sales (P/S): 5.97
• P/FCF Ratio: 12.95
• Enterprise Value/Market Cap: 1.22
• Enterprise Value/Revenue: 7.87
• Enterprise Value/Gross Profit: 9.31
• Enterprise Value/Ebitda: 11.03
• 1Y Price Target: $77.63
• Price Target Upside: 13.99% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): 6.27
• Revenue Forecast (FY): $1.34B

• Rating: 74 Outperform
• Price Target: $76.00 ▲(11.60% Upside)

Halozyme's strong financial performance and positive earnings call outlook are the most significant factors driving the score. The company's robust profitability and growth prospects are slightly offset by high leverage and a neutral technical analysis. The reasonable valuation further supports the stock's attractiveness.

Positive Factors

Revenue Growth

The significant increase in royalty revenue reflects strong demand for Halozyme's technologies, indicating robust growth potential and market acceptance.

Strategic Partnerships

The collaboration with Merus expands Halozyme's reach and potential revenue streams, enhancing its competitive position in the biotech industry.

FDA Approval

FDA approval for a new indication strengthens Halozyme's product portfolio, potentially driving long-term revenue growth and market leadership.

Negative Factors

High Leverage

Significant leverage can limit financial flexibility and increase risk, potentially impacting long-term financial health and investment capacity.

Decrease in Collaboration Revenues

The decline in collaboration revenues may indicate challenges in achieving milestones, affecting future revenue stability and growth.

Pending Acquisition

Delays in acquisition completion could hinder strategic expansion plans and delay anticipated synergies, affecting growth projections.

Halozyme Business Overview & Revenue Model

Company Description

Halozyme Therapeutics, Inc. (HALO) is a biotechnology company specializing in the development and commercialization of novel therapeutics for patients with unmet medical needs. The company focuses primarily on drug delivery solutions and the development of enzymatic therapies that facilitate the subcutaneous delivery of biologics. Halozyme’s core product, Hylenex, is an injectable formulation of hyaluronidase that enhances the absorption and dispersion of other injected drugs, making it a valuable tool in various therapeutic areas including oncology and diabetes.

How the Company Makes Money

Halozyme generates revenue through a combination of product sales, royalties, and collaborations with pharmaceutical companies. The company earns significant income from its proprietary products, particularly Hylenex, which is used in various therapeutic applications. Additionally, Halozyme enters into partnership agreements with larger pharmaceutical firms, allowing these companies to utilize its proprietary enzyme technology in their drug development processes. These collaborations often include upfront payments, milestone payments, and ongoing royalties based on the sales of products that incorporate Halozyme's technology. Partnerships with major companies in the biotech and pharmaceutical sectors further enhance Halozyme's revenue streams, positioning the company to benefit financially from the success of its partners' products.

Halozyme Financial Statement Overview

Summary

Halozyme exhibits strong financial performance with impressive revenue and profit growth, efficient operations, and solid cash flow generation. However, the high leverage poses potential risks, and maintaining profitability amidst cost pressures will be crucial for future stability.

Income Statement

Halozyme demonstrates strong revenue growth with a 5.45% increase in TTM, supported by high gross and net profit margins of 84.20% and 47.28%, respectively. The company maintains robust EBIT and EBITDA margins, indicating efficient operations and profitability. However, the net profit margin has slightly decreased from previous years, suggesting potential cost pressures.

Balance Sheet

The company shows a high debt-to-equity ratio of 4.54, indicating significant leverage, which could pose financial risk. However, the return on equity is strong at 136.63%, reflecting effective use of equity to generate profits. The equity ratio is relatively low, suggesting a reliance on debt financing.

Cash Flow

Halozyme's cash flow performance is solid, with a free cash flow growth rate of 11.41% in TTM and a high operating cash flow to net income ratio of 4.08. The free cash flow to net income ratio is nearly 1, indicating efficient cash generation relative to earnings. However, the reliance on debt may impact future cash flow stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.24B	1.02B	829.25M	660.12M	443.31M	267.59M
Gross Profit	1.05B	855.91M	636.89M	520.81M	361.90M	224.23M
EBITDA	886.43M	656.54M	451.95M	315.51M	259.04M	152.96M
Net Income	595.49M	444.09M	281.59M	202.13M	402.71M	129.09M
Balance Sheet
Total Assets	2.22B	2.06B	1.73B	1.84B	1.10B	579.92M
Cash, Cash Equivalents and Short-Term Investments	701.96M	596.07M	336.00M	362.79M	740.92M	368.01M
Total Debt	1.51B	1.51B	1.50B	1.51B	876.67M	397.23M
Total Liabilities	1.72B	1.70B	1.65B	1.67B	907.48M	428.88M
Stockholders Equity	503.92M	363.82M	83.81M	169.80M	196.95M	151.05M
Cash Flow
Free Cash Flow	602.40M	468.37M	373.28M	235.30M	297.98M	52.95M
Operating Cash Flow	611.00M	479.06M	388.57M	240.11M	299.44M	55.45M
Investing Cash Flow	225.46M	-262.72M	-96.91M	-487.00M	-406.29M	78.35M
Financing Cash Flow	-571.10M	-218.86M	-407.99M	362.37M	77.86M	-106.28M

Halozyme Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 68.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HALO, the sentiment is Negative. The current price of 68.1 is below the 20-day moving average (MA) of 69.94, below the 50-day MA of 68.92, and above the 200-day MA of 63.04, indicating a neutral trend. The MACD of 0.40 indicates Positive momentum. The RSI at 40.19 is Neutral, neither overbought nor oversold. The STOCH value of 19.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HALO.

Halozyme Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CORT	77 Outperform	$8.39B	91.16	16.47%	―	17.92%	-26.13%
HALO	74 Outperform	$8.01B	14.31	124.50%	―	31.19%	59.01%
TECH	64 Neutral	$9.81B	128.68	3.80%	0.50%	3.85%	-48.17%
ROIV	61 Neutral	$14.06B	―	-14.73%	―	-83.82%	-109.22%
IONS	58 Neutral	$13.17B	-47.51	-39.99%	―	20.39%	34.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MRNA	50 Neutral	$9.44B	―	-29.32%	―	-56.00%	-38.95%

Halozyme Corporate Events

Halozyme Therapeutics Reports Strong Q3 2025 Results

Halozyme Therapeutics is a biopharmaceutical company known for its ENHANZE drug delivery technology, which facilitates subcutaneous delivery of injected drugs, aiming to improve patient experiences and outcomes. The company is headquartered in San Diego, CA, and collaborates with major pharmaceutical companies worldwide.

Halozyme Raises 2025 Guidance After Strong Q3 Results

Halozyme Therapeutics announced a transition plan for its CFO, Nicole LaBrosse, who will remain in her role until a successor is found or until March 2026. The company reported strong financial results for Q3 2025, with significant increases in revenue and net income, and raised its financial guidance for 2025, driven by the success of its ENHANZE technology and strategic acquisitions, such as the planned acquisition of Elektrofi.

The most recent analyst rating on (HALO) stock is a Hold with a $65.00 price target. To see the full list of analyst forecasts on Halozyme stock, see the HALO Stock Forecast page.

Halozyme Confirms Minimal Impact from Medicare Guidance

On October 14, 2025, Halozyme Therapeutics issued a statement regarding the U.S. Centers for Medicare & Medicaid Services’ final IPAY 2028 guidance for Medicare price negotiations. The statement highlights that the guidance will have zero to minimal impact on the company’s future royalty revenues from ENHANZE® partner products through at least 2035. Halozyme’s research demonstrates significant cost savings and clinically meaningful benefits of subcutaneous (SC) delivery over intravenous (IV) delivery, with SC delivery preferred by a majority of patients. This development reinforces Halozyme’s strong positioning in the market by showcasing the advantages of its ENHANZE® technology in reducing healthcare costs and improving patient outcomes.

The most recent analyst rating on (HALO) stock is a Sell with a $70.00 price target. To see the full list of analyst forecasts on Halozyme stock, see the HALO Stock Forecast page.

Halozyme Appoints New Chief Operating Officer

On October 1, 2025, Halozyme Therapeutics appointed Cortney Caudill as Senior Vice President, Chief Operating Officer. Ms. Caudill, who joined Halozyme in October 2023, brings extensive experience from her previous roles at Aeglea Biotherapeutics and other life sciences companies. Her appointment is expected to bolster Halozyme’s operational capabilities, with her compensation package including a $600,000 base salary and equity awards, aligning her incentives with the company’s long-term growth objectives.

The most recent analyst rating on (HALO) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Halozyme stock, see the HALO Stock Forecast page.

Halozyme Announces Merger Agreement with Elektrofi

On September 30, 2025, Halozyme Therapeutics, Inc. announced a merger agreement with Elektrofi, Inc., where Elektrofi will become a wholly-owned subsidiary of Halozyme. The deal involves an upfront payment of $750 million and potential milestone payments, with the merger subject to customary conditions and regulatory approvals.

The most recent analyst rating on (HALO) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Halozyme stock, see the HALO Stock Forecast page.

Halozyme Acquires Elektrofi to Enhance Drug Delivery

On October 1, 2025, Halozyme announced its acquisition of Elektrofi, a company specializing in ultra-high concentration microparticle technology for biologics, known as Hypercon. This strategic move, approved by both companies’ boards, involves an upfront payment of $750 million and potential milestone payments. The acquisition aims to expand Halozyme’s drug delivery offerings and support long-term revenue growth through Elektrofi’s scalable licensing model. The Hypercon technology allows for higher protein concentrations, facilitating more convenient at-home and healthcare provider office delivery. This acquisition is expected to enhance Halozyme’s industry positioning and provide significant growth opportunities, with royalty revenues anticipated to begin by 2030.

The most recent analyst rating on (HALO) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Halozyme stock, see the HALO Stock Forecast page.

Halozyme Therapeutics’ Earnings Call Highlights Robust Growth

Halozyme Therapeutics’ recent earnings call painted a picture of robust financial growth and strategic advancements, tempered by challenges in intellectual property and regulatory landscapes. The company’s raised guidance underscores a strong outlook, yet potential hurdles remain on the horizon.

Halozyme Therapeutics Reports Strong Q2 2025 Results

Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on enhancing patient experiences with its ENHANZE drug delivery technology, facilitating subcutaneous delivery of medications. The company operates in the healthcare sector and is known for its innovative solutions in drug delivery.